Background: Risk stratification of elderly patients presenting with heart failure (HF) to an emergency department (ED) is an unmet challenge. We prospectively investigated the prognostic performance of different biomarkers in unselected older patients in the ED. Methods: We consecutively enrolled 302 non-surgical patients ⩾70 years presenting to the ED with a wide range of cardiovascular and non-cardiovascular comorbid conditions. N-terminal pro-B-type natriuretic peptide (NT-proBNP), mid-regional pro-adrenomedullin (MR-proADM), mid-regional pro-atrial natriuretic peptide (MR-proANP), C-terminal pro-endothelin-1 (CT-proET-1), ultrasensitive C-terminal pro-arginine-vasopressin (Copeptin-us) and high-sensitivity cardiac troponin T (hs-cTnT) were measured at admission. Two cardiologists independently adjudicated the final diagnosis of HF after reviewing all available baseline data using circulating NT-proBNP levels. A final diagnosis of HF was found in 120 (40%) of the 302 patients. All patients were followed up for cardiovascular death within the following 12 months. In order to test the prognostic performance of the investigated biomarkers we used boosting models with age and sex as mandatory covariates. Boosting is a statistical learning technique with built-in variable selection developed to obtain sparse and interpretable prediction models. Results: Follow-up was 100% complete. During a median follow-up time of 225 days (interquartile range (IQR) 156-319 days), 30 (9.9%) of 302 patients (aged 81±6 years) had cardiovascular deaths. Of these 30 patients, 21 had HF and nine had no HF diagnosed prior to admission. The boosting model selected MR-proADM and hs-cTNT as predictors of cardiovascular deaths. The median values of MR-proADM and hs-cTnT at presentation were significantly higher in patients with cardiovascular deaths compared to surviving patients during follow-up (2.56 nmol/L (IQR 1.62-4.48) vs. 1.11 nmol/L (IQR 0.83-1.80), P<0.001 and 81 ng/L (IQR 38-340) vs. 17 ng/L (IQR 0.9-38), P=0.004). One unit increase in the log-transformed MR-proADM levels was associated with a 1.99-fold risk of death (95% confidence interval (CI) 1.61-2.45, P<0.001). The second marker, hs-cTnT, showed an increased predicted risk but was not significantly correlated to event-free survival (hazard ratio 3.22, 95% CI 0.97-10.68, P=0.056). Conclusion: Within different biomarkers, MR-proADM was the only predictor of cardiovascular deaths in unselected older patients presenting to the ED.
Introduction
Patients >70 years old constitute an increasing proportion of all patients who present to the emergency department (ED) for diagnosis of heart failure (HF). 1 In patients with stable chronic HF, a hospitalisation for worsening HF or myocardial infarction is associated with substantially increased risk of subsequent death even with contemporary extensive background pharmacological therapy. The risk is most pronounced in the early phase of hospitalisation but remains relatively high even after 18 months. 2 Many of these patients have one or more comorbidities such as chronic obstructive pulmonary disease, obesity, anaemia or chronic venous insufficiency. Comorbidities are important in older patients with HF because most of them are associated with worse clinical status and are predictors of poor prognosis in HF. 3 Early identification of older patients at higher risk of adverse events could lead to earlier intervention that could potentially improve outcomes. However, symptoms or signs of HF might be substantially less clear in older patients compared to younger individuals, and they may be more difficult to detect due to the presence of comorbid conditions. 4 Measurement of biomarkers may help to refine risk stratification over models that consider clinical variables alone in older patients admitted to the ED. 5 High N-terminal pro-B-type natriuretic peptide (NT-proBNP) is well validated and represents an acknowledged standard for diagnosis of HF. In a previous study, we have shown the improved diagnostic accuracy of C-terminal pro-endothelin-1 (CT-proET-1) or mid-regional pro-adrenomedullin (MR-proADM) in addition to NT-proBNP for diagnosis of HF in older patients. 6 However, the effectiveness of NT-proBNP for prognostic purposes in this cohort of elderly patients is not well characterised. 5, 7 NT-proBNP increases not only with age often due to an impaired renal function, but also differs for comorbid patients presenting with acute onset or worsening of symptoms to a ED and those presenting with a more gradual onset of symptoms. 3, 8 To overcome the limitations of NT-proBNP in the diagnosis of HF, the use of novel biomarkers may be helpful to improve prognostic discrimination in older patients presenting to the ED.
The biological activity of adrenomedullin in the cardiovascular system is similar to that of NT-proBNP, although it is produced in response to different stimuli in the peripheral circulation. Adrenomedullin causes vasodilatation, 9 increases cardiac output, 10 and induces diuresis and natiuresis. 11 Conversely, the peripheral vasoconstrictor endothelin, adrenomedullin's counterpart, has anti-natriuretic and mitogenic properties. 12 Plasma levels of both peptides are elevated in HF and have been suggested to be of prognostic value. 13 Atrial natriuretic peptide is a sister peptide to the B-type natriuretic peptide and is prognostically equivalent to NT-proBNP in HF. Arginine vasopressin levels are also known to be elevated in HF and its actions in promoting salt and water retention and as a vasoconstrictor are well documented. 14 The aim of the present study was to test the prognostic performance of different biomarkers including NT-proBNP, MR-proADM, high-sensitivity cardiac troponin T (hs-cTnT), mid-regional pro-atrial natriuretic peptide (MR-proANP), CT-proET-1 or ultra-sensitive C-terminal pro-arginine-vasopressin (Copeptin-us) for cardiovascular death within the following 12 months in unselected older patients presenting to the ED.
Methods

Study design and population
From 18 January 2011 to 5 September 2011, we measured NT-proBNP, hs-cTnT, MR-proADM, MR-proANP, CT-proET-1 and Copeptin-us as part of the routine blood sampling protocol upon admission of all consecutive nontrauma patients aged ⩾70 years who were admitted to the ED of a large tertiary care centre in Nuernberg, Germany. Exclusion criteria were acute ST-elevation myocardial infarction, planned elective coronary revascularisation, hospitalisation for unstable angina within the preceding 2 months, coronary artery bypass grafting or percutaneous transluminal angioplasty within the preceding 3 months. Patients were also excluded if they had renal failure requiring dialysis, trauma with suspected myocardial contusion, life expectancy less than 6 months, or if they did not consent to providing a blood sample for use by the research team. The study conformed to the principles outlined in the Declaration of Helsinki and was conducted after approval by the ethics committee of the Friedrich-Alexander University. All patients or their guardians provided written informed consent.
Clinical characteristics
All patients underwent a standard clinical work-up, including patient history, physical examination, standard 12-lead electrocardiography, non-invasive blood pressure measurement and laboratory analyses. The New York Heart Association (NYHA) classification, Barthel index and Charlson comorbidity index were assessed in all patients. [15] [16] [17] Bedside echocardiography (Vivid S6 cardiovascular ultrasound system; GE Healthcare, Madison, USA) was performed on all patients by an attending cardiologist at the ED. Left ventricular ejection fraction (LVEF) was calculated by Simpson's rule and wall motion severity index using the American Society of Echocardiography 16 segment model. 18 Assessment of left ventricular systolic function allowed subclassification of preserved (LVEF ⩾55%), subnormal (LVEF <45%) or borderline (55%> LVEF ⩾45%) LVEF function. Doppler and tissue Doppler measurements of the longitudinal function of the heart were used to determine left ventricular diastolic dysfunction. E/e′ measurements were recorded at both the septum and lateral wall. 19 HF with preserved ejection fraction (HFpEF) was diagnosed in accordance with European Society of Cardiology (ESC) guidelines using clinical, echocardiographic and NT-proBNP measurements. Patients with clinical features of HF whose LVEF was >50% with E/e′ >15, or those with an equivocal E/e′ of 8-15 but NT-proBNP >220 pg/mL were diagnosed as having HFpEF. 19 Thus, reference standard determination of left ventricular systolic dysfunction (LVSD) and HFpEF were clinically determined by interpreting echocardiographic findings augmented with the results from standard testing. A follow-up for cardiovascular death was performed during the index hospital stay and within the following 12 months after discharge by telephone contact with the patients and their practitioners.
Adjudicated final diagnosis
To determine the final diagnosis for each patient, two cardiologists (AB and PB) independently reviewed all available medical records of the index hospital stay, including clinical history, findings from physical examination, results of laboratory tests including NT-proBNP, but not using the other biomarkers examined (MR-proADM, MR-proANP, CT-proET-1 and Copeptin-us assays), radiographic studies, electrocardiography and echocardiography. HF was diagnosed when typical signs and symptoms in combination with objective evidence of an abnormality of cardiac structure or function at rest based on the definition of the ESC guidelines was present. 3 Disagreement regarding final classification occurred in 4% of the cases and was resolved by consensus involving a third cardiologist (MC).
Laboratory analysis
Routine laboratory parameters, including hs-cTnT, C-reactive protein, creatinine and NT-proBNP were measured immediately after blood withdrawal by standardised methods. In addition, potassium ethylenediamine tetraacetic acid (EDTA) plasma samples for MR-proADM, MR-proANP, CT-proET-1, Copeptin-us and Cystatin C measurement were collected at the time of the patient's admission to the ED, centrifuged and frozen at −80°C until they were analysed in a blinded fashion in one batch at the core laboratory of the Nuernberg Hospital during a secondary laboratory assessment. Laboratory analyses were done without knowledge of clinical presentation.
Cardiac troponin T was measured using the hs-cTnT assay (Roche Diagnostics, Mannheim, Germany) in all patients with electrochemiluminescence immunoassay (ELICA) technology on a cobas e411 system (Roche Diagnostics, Mannheim, Germany). The limit of blank was 0.003 ng/mL and the limit of detection was 0.005 ng/mL. The 99th percentile cut-off was 0.014 ng/mL, which was used as the diagnostic cut-off, the coefficient of variation (CV) <10 at 0.013 ng/mL. 20 NT-proBNP was assayed on a cobas e411 system (Roche Diagnostics, Mannheim, Germany) using the Roche NT-proBNP II electrochemiluminescent sandwich assay. The measuring range was 5-35,000 pg/mL. The functional assay sensitivity that is the lowest analytic concentration that can be )) has been published previously. 21 Copeptin was measured using the Copeptin-us assay (Thermo Scientific B.R.A.H.M.S GmbH, Hennigsdorf, Germany) in potassium EDTA plasma samples with the time resolved amplified cryptate emission (TRACE) technology on a KRYPTOR compact PLUS system (Thermo Scientific B.R.A.H.M.S GmbH, Hennigsdorf, Germany). 22 The limit of detection was 0.9 pmol/L and the measuring range with automatic dilution was from 0.9 to 2000 pmol/L. The assay has a functional assay sensitivity (lowest value with an interassay CV <20%) <2.0 pmol/L. Cystatin C, a more precise biomarker of the glomerular filtration rate, was measured using a Dako Cystatin C assay (Dako A/S, Glostrup, Denmark) in potassium EDTA plasma samples by turbidimetry on an AU 640 CC system (Beckman Coulter, Krefeld, Germany). The limit of detection was 0.028 mg/L and the measuring range 0.4-8.0 mg/L. The 95th percentile cut-off for individuals >50 years was 1.44 mg/L, which was used as the diagnostic cut-off.
Statistical analysis
Continuous variables are expressed as mean ± standard deviation, or as median (25%/75% quantiles) for skewed variables and categorical data as absolute numbers and percentages. Categorical variables were compared using the Pearson χ 2 test, while Student's t test and analysis of variance or Mann-Whitney U test were used to compare continuous variables.
In order to assess the prognostic performance of the investigated biomarkers we used boosting methods. [23] [24] [25] Boosting starts with a null model (in our case a model that contains only the mandatory covariates age and sex) and computes the negative gradient of the loss function, which can be thought of as working residuals. Next, all candidate variables are added separately to the model, one at a time.
Only the candidate variable that best fits the outcome (or the negative gradient of the loss function in the current step to be more precise) is updated. Candidate variables were all biomarkers and the clinical covariates body mass index, respiratory rate, systolic blood pressure, number of cardiovascular risk factors, chronic kidney disease stage, NYHA class, Barthel index, Charlson comorbidity index, LVEF, LVEF ⩽50%, LVEF <35% and Cystatin C level at presentation. One adds the best-fitting variable to the model but only uses a fraction of the estimated effect (10%) to allow further variables to be included in later steps even if these are highly correlated. The negative gradient (i.e. the working residuals) are recomputed and one repeatedly adds all variables (including the ones that were already added) and updates the best fitting variable until one reaches a fixed number of steps. To avoid overfitting we used crossvalidation with 25-fold subsampling, that is, we re-run the modelling process on random subsets of the data and evaluated the fit on the data that were not used to fit the model. This mimics the behaviour of the model for new data and hence helps to avoid finding spurious features and thus finding a model that is generalisable to new data.
We used the boosting approach with a linear Cox model. As sensitivity analysis we additionally fitted a Cox model with stumps (i.e. trees with a single split) and an additive Cox model with non-linear covariate effects. The covariates age and sex were used as mandatory linear effects in all boosting models. All models selected MR-proADM and hs-cTnT at presentation. Finally, we re-fitted the linear Cox model with these two variables in addition to the two mandatory covariates age and sex using a standard Cox model and investigated their relation to the predefined end point. Hazard ratios (HR) were given for an increase of one unit in the tested log-transformed biomarker. A second sensitivity analysis was conducted to evaluate the prognostic performance of the standard diagnostic biomarker NT-proBNP. We therefore re-fitted the boosting models with NT-proBNP as an additional mandatory covariate. Again, MR-proADM and hs-cTnT at presentation were selected as prognostic factors and the model was evaluated using a standard Cox as before.
The cross-validated cumulative survival area under the curve (AUC) was computed for the linear boosting model to assess the predictive performance of the estimated survival model. 26 We used 10-fold cross-validation. In each of the 10-folds we tuned the model using subsampling as described above. We used only the learning data and evaluated the model on the remaining 1/10th of the data that was not used for model fitting.
All performed tests values were two-sided and a significance level of P<0.05 was considered. All calculations were done with R 27 and IBM SPSS Statistics version 21.0.0 (IBM Inc., Somers, NY, USA). Boosting methods are implemented in the R package mboost 28 and time-dependent receiver operating characteristic curves and c-index are implemented in the R package survAUC. 29 
Results
Clinical characteristics
We recruited 332 patients who met the inclusion criteria, of whom 30 had one or more of the prespecified exclusion criteria (Figure 1) . The final population of 302 patients with a wide range of cardiovascular and non-cardiovascular comorbid conditions -in whom both the reference standard and the index tests NT-proBNP, MR-proADM, MR-proANP, CT-proET-1, Copeptin-us and hs-cTnT existed -was further analysed. One hundred and sixty-five (55%) of the 302 patients had a preserved LVEF; 137 (45%) had LVSD, of these, 72 (53%) had a subnormal and 65 (47%) a borderline left ventricular function. The baseline characteristics of patients with confirmed HF (n=120) compared to patients without HF (n=182) were different in respect to some demographic, echocardiographic and laboratory data (see Tables 1 and 2 ).
Adjudicated final diagnosis using the reference standard
A final diagnosis of HF was found in 120 (40%) of the 302 patients. These patients were admitted to the ED for a variety of reasons such as chest pain, breathlessness, palpitations, lower extremity oedema, functional impairment, cognitive impairment and mobility disorders. All were hospitalised at the index visit. The cause of HF according to the ESC classification was decompensated chronic HF in 40 (33%), lung oedema in four (3%), hypertensive HF in 39 (33%), cardiogenic shock in two (2%), isolated right ventricular HF in 11 (9%) and acute coronary syndrome and HF in 24 (20%) patients. Eighty-seven (72%) HF patients had LVSD, of these, 56 (64%) had a subnormal and 31 (36%) a borderline left ventricular function (Figure 1 ). HFpEF was seen in 33 (28%) patients (14 patients with an E/e′ of 8-15 and NT-proBNP >220 pg/ml and 19 patients with an E/e′of >15). In the re-fitted multivariate Cox model, MR-proADM treated as a continuous variable was strongly related to the event-free survival. After adjustment for age and sex, one unit increase in the log-transformed MR-proADM levels was associated with a 1.99-fold risk of death (95% CI 1.61-2.45, P<0.001; Table 3 ). The second marker hs-cTnT showed an increased predicted risk but was not significantly related to the event-free survival (HR 3.22, 95% CI 0.97-10.68, P=0.056; Table 3 ).
Effect of index tests on prognosis
To assess the prognostic power of NT-proBNP we refitted the boosting models with NT-proBNP as an additional mandatory covariate. We obtained very similar results as before. Again MR-proADM and hs-cTnT at presentation were selected in all models. We added NT-proBNP to the standard Cox model, which had no effect on survival prognosis (HR 1.00, 95% CI 1.00-1.00, P=0.409). Furthermore, adding NT-proBNP to the standard Cox model hardly changed the estimated effects of the remaining markers or the significant associations of age and MR-proADM (Table 4 ).
Discussion
The present study tested the prognostic performance of different biomarkers including MR-proADM, hs-cTnT, MR-proANP, CT-proET-1, Copeptin-us, NT-proBNP and hs-cTnT for cardiovascular death within the following 12 months in unselected older patients presenting to the ED. Our robust results indicate that only MR-proADM improved risk stratification in this study population with a high risk of cardiovascular disease.
The BACH study reports that MR-proADM was prognostically more accurate than B-type natriuretic peptide and NT-proBNP at predicting short to middle term outcome in patients presenting to hospital with acute shortness of Data presented as n (%) of patients, mean ± SD for even variables, or median and 25%/75% quantiles for skewed variables. NYHA: New York Heart Association; ACE: angiotensin-converting enzyme.
All P values are descriptive only.
No formal testing is considered. P values describe differences between patients with or without heart failure. Data presented as n (%) of patients, mean ± SD for even variables, or median and 25%/75% quantiles for skewed variables. NT-proBNP: N-terminal pro-B-type natriuretic peptide; MR-proADM; mid-regional pro-adrenomedullin; MR-proANP: mid-regional pro-atrial natriuretic peptide; CT-proET-1: C-terminal pro-endothelin-1; Copeptin-us: ultra-sensitive C-terminal pro-vasopressin, hs-cTnT: high-sensitivity troponin T.
All P values are descriptive only. No formal testing is considered. P values describe differences between patients with or without heart failure.
breath and HF. 30 A recent study by Bjurman et al. revealed that older decompensated HF patients required significantly higher levels of NT-proBNP (>8000 pg/ml) than younger patients to demonstrate an increased risk of adverse outcome. 31 A multimarker strategy including Cystatin C >1.3 mg/L, troponin T >10 ng/L and age over 75 years improved risk stratification for 3-year mortality, in particular in older patients with moderately elevated NT-proBNP (2000-8000 pg/ml). But unlike us, they were unable to include many of the novel biomarkers that are emerging in clinical practice, such as MR-proADM, MR-proANP, CT-proET-1 and Copeptin-us. 31 In contrast to our study population, the above-mentioned studies were from a selected younger HF population with LVSD. Our study population consists of unselected older patients from 'real life' with significant comorbidities including patients with both LVSD and HFpEF. Most prognostic studies that included B-type natriuretic peptide or NT-proBNP assessments were performed in patients whose mean age was under 68 years. 32 As shown in our study, natriuretic peptides lack sufficient validation in older patients with HF. The moderately elevated NT-proBNP in our study population with HF indicates a moderate risk in affected patients, and NT-proBNP proved not to be a significant risk predictor. In several multicentre studies, MR-proADM was demonstrated to be even better than the established natriuretic peptides in the identification of HF patients at highest risk of death, particularly for short-term outcomes. 33 Furthermore, MR-proADM proved to be an important prognostic humoral marker, especially in mild/ moderately symptomatic and non-ischaemic HF patients with LVSD. 34 While patients with HF showed MR-proADM values that were increased more than five-fold above the normal reference range, patients without HF had almost three times higher MR-proADM values in our study. Of note, MR-proADM is typically increased in those at high risk of cardiovascular disease, such as elderly patients, because its strongest correlations were found with age and kidney function in both univariate and multivariate analyses in the PREVEND study. 35 Increased levels of hs-cTnT have also been associated with worse prognosis in prevalent HF. The Val-HeFT study has shown that minor elevations of circulating hs-cTnT predict adverse outcomes in patients with HF. 34 A small study found an association between worsening LVEF and baseline troponin level. 36 In fact, both myocardial strain and myocyte death, two related mechanisms, may contribute to troponin elevations. In our study, hs-cTnT did not independently contribute to the multivariable model probably due to the limited sample size of the study population.
Measurements of circulating biomarkers are associated with additional costs. To be clinically useful, measurement of a biomarker should influence clinical management in a cost-effective manner -either by improving diagnosis or by refining risk stratification or guiding therapy. Of note, former work on the impact of MR-proADM on primary patient disposition of undifferentiated patients presenting to the ED with acute dyspnoea showed that MR-proADM can guide an optimised patient disposition from the ED and might therefore help to optimise hospital resource utilisation as well as patient care. 37 Of interest, risk management of HF in older patients is ambiguous and challenging due to atypical presentation of HF in older patients and a wide variation of cut-off levels of natriuretic peptides. In addition, echocardiographic imaging is time consuming and challenging in older patients but according to current guidelines is recommended to make the diagnosis of HF. 3 It is thus tempting to speculate that the use of MR-proADM may reduce overall management costs of unselected older patients presenting to the ED.
Study limitations
Some limitations of this prognostic study have to be acknowledged: this study has only a moderate sample size of older patients admitted to the ED for various symptoms. Thus, a generalisation of the study results should be undertaken with caution. A validation of the current findings in a larger sample size of older patients might be valuable. A definite 'gold standard' for the diagnosis of HF is lacking and needs consideration of several features, including signs and symptoms of HF including evidence for cardiac dysfunction. However, a final adjudicated diagnosis was established considering currently recommended standards supporting the high quality of this analysis. We did not limit our patient cohort to individuals presenting with shortness of breath. This was done to account for the atypical presentation of older patients with acute cardiac disease. NT-proBNP was used for adjudication of the diagnosis 'heart failure'. Possibly, this may have influenced its contribution in the risk model. But while NT-proBNP is the gold standard for the diagnosis of HF, our analysis suggests that it had no impact on the prognosis of older patients with HF.
Conclusion
Our findings suggest that -within different biomarkers including NT-proBNP, hs-cTnT, MR-proADM, MR-proANP, CT-proET-1 and Copeptin-us -only MR-proADM demonstrates potential to assist clinicians in predicting the risk of cardiovascular death within the following 12 months in unselected older patients presenting to the ED.
